In the previous study, a new delivery nanoparticle containing both tumor-penetrating peptide (internalizing RGD peptide, iRGD) and EGFR single-domain antibody (sdAb) was constructed, the anti-EGFR-iRGD recombinant protein was modified on the surface of red blood cell membrane-coated nanoparticle (RBCm-NP), and GA was loaded. This evidence concerns the gene EGFR and neoplasm.